
pm et
summari compani global research-bas pharmaceut busi key drug
humira rheumatoid arthriti indic
price-to-earnings oper ep
heavili reliant one drug humira
current account sale howev
recently-approv drug like help diversifi sale
past perform indic futur perform reli upon
analysi prepar equiti analyst
sep pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra reiter
lower
target below-p
ep estim
see risk relat california insur
commission lawsuit entranc
humira biosimilar europ ep
vs higher estim
rais ep
ep sale
increas organ
billion imbruvica net revenu grew
expect million
humira sale grew billion
outsid ou sale humira grew
organ ahead mid-octob
introduct ou biosimilar see
initi price eros ou humira
stronger end
expect includ
continu double-digit earn growth
higher sg cost due invest new
product launch particularli upadacitinib
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview abbvi inc global research-bas drug busi emerg separ
compani follow spin-off abbott sharehold share-for-shar
basi januari compani develop market therapi address major complex
seriou diseas product focus treat condit chronic autoimmun diseas
rheumatolog gastroenterolog dermatolog oncolog includ blood cancer virolog includ
hepat viru hcv human immunodefici viru hiv neurolog disord
parkinson diseas multipl sclerosi metabol diseas includ thyroid diseas
complic associ cystic fibrosi seriou health condit compani also
pipelin new medicin clinic develop across medic specialti immunolog
oncolog neurolog addit target invest cystic fibrosi women health
key product humira inject biolog tnf tumor necrosi factor blocker treatment
rheumatoid arthriti ra similar condit estim humira account half
global prescript drug market rheumatoid arthriti besid moder sever ra adult
humira also approv mani use includ juvenil idiopath arthriti psoriasi ankylos
spondyl ulcer coliti crohn diseas axial spondyloarthr
humira composit matter patent expir end equival european union
patent set expir eu countri april competitor rheumatoid arthriti market
includ remicad market johnson johnson simponi johnson johnson enbrel
although humira patent expir decemb confid patent
surround humira number patent includ formul manufactur method
treatment abl protect biosimilar challeng least
imbruvica ibrutinib oral once-daili therapi inhibit protein call bruton tyrosin kinas
imbruvica approv treatment adult patient chronic lymphocyt leukemia cll /small
lymphocyt lymphoma sll cll/sll delet mantl cell lymphoma receiv
least one prior therapi waldenstrm macroglobulinemia margin zone lymphoma requir
system therapi receiv least one prior therapi chronic graft versu
host diseas failur one line system therapi
venclexta venetoclax approv treat peopl cll delet receiv least
one prior treatment venclexta food drug administr fda -approv treatment
target b-cell lymphoma protein support cancer cell growth overexpress major
patient cll venclexta approv eu treatment cll patient
delet mutat unsuit fail b-cell receptor pathway inhibitor
treatment cll absenc delet mutat fail
chemoimmunotherapi b-cell receptor pathway inhibitor
mavyret glecaprevir/pibrentasvir approv unit state european union maviret
treatment patient chronic hcv genotyp infect without cirrhosi
compens cirrhosi child-pugh also indic treatment adult patient hcv
genotyp infect previous treat regimen contain hcv inhibitor
proteas inhibitor eight-week pan-genotyp treatment patient
without cirrhosi new treatment
pipelin june pipelin compound indic phase ii
women health oncolog multipl sclerosi well parkinson alzheim diseas
financi trend sale increas billion billion mainli
success humira imbruvica repres three-year compound annual growth rate compound-annual-growth-rate
gross margin increas research develop
cost increas billion sale billion sale adjust
ep increas repres three-year compound-annual-growth-rate
execut vice-president extern
oper
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued
neutral sinc octob technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook biotechnolog
sub-industri tradit defens
next month posit reflect
favor prospect commerci
new therapi biotechnolog compani
trade signific discount
market think remedi
robust pipelin drug brought market
fda approv new drug
sinc record
approv think mani
newly-approv drug drug late-stag
clinic trial consider commerci
prospect repres major advanc
therapi diseas cystic fibrosi
hepat multipl sclerosi cancer
exampl fda approv first
gene-therapi drug genet alter
patient immun cell first-ev
think growth biotechnolog stock
slightli limit high drug price
us heighten scrutini
us polit apparatu last
year despit talk lower drug
price seen particularli sever
measur taken us govern lower
drug price far center medicar
 medicaid introduc option step
therapi part drug attempt lower
treatment cost current administr
also propos elimin rebat
drug manufactur pay pharmaci benefit
manag neither measur
like significantli impact drug
manufactur think mid-term
elect earli novemb could provid
insight futur regulatori propos
anoth sourc price pressur drug
manufactur pharmaci benefit manag
pbm health insur exert
influenc drug prescript
price pressur like increas
health care industri continu
consolid merger note includ
cvs-aet ci-esrx combin
expect wider adopt biomark
research genetic-target clinic
studi bolster long-term pipelin
product merger acquisit
 climat near futur appear
favor larg pharmaceut
biotechnolog firm look off-set
lost revenu expir patent
matur product promis late-stag
compani low debt level modest
valuat reason favor
biolog price competit
innov act bpcia grant
exclus period brand biolog
aggress use patent law
delay commerci biosimilar
effect extend period
result expect biosimilar advanc
slowli next sever year howev
biosimilar approv
introduc expect growth
biosimilar acceler
year date septemb
 biotech index rose vs
rise
biotech index rose vs rise
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra keep buy opinion share inc
lower target price line
peer ep estim balanc robust
growth concern rova-t compound disappoint data
phase trial third line small cell lung cancer patient data rais
concern rova-t trial on-going rova-t phase trial
first second line set small cell lung cancer ep vs
ahead estim rais ep estim
sale includ fx benefit rose humira sale
imbruvica sale spite disappoint data rova-t view
bla risankizumab treat plaqu psoriasi expect data sever
compound throughout year begin tender offer
share part stock buy-back /jeffrey loo cfa
et cfra reiter buy opinion share inc
rais target peer
ep estim faster growth set
ep ep vs ahead view sale
rose humira sale imbruvica rose consist
 sale profit share encourag
result view strong pipelin guid sale
ep midpoint partli aid tax
reform see effect tax rate
rais target in-lin peer
forward ep estim ep vs
ahead view rais ep estim provid
ep guidanc line view sale grew
humira sale imbruvica expect humira sale
approach believ achiev follow patent
settlement also encourag pipelin develop
recent nda file elagolix endometriosi /jeffrey loo cfa
analyst research note compani news
et cfra reiter hold opinion share inc
lower target below-p
ep estim see risk relat
california insur commission lawsuit entranc humira
biosimilar europ ep vs higher
estim rais ep ep
sale increas organ billion
imbruvica net revenu grew expect million
 humira sale grew billion outsid ou sale
humira grew organ ahead mid-octob introduct ou
biosimilar see initi price eros ou humira
stronger end manag expect commun
includ continu double-digit earn growth higher
sg cost due invest new product launch particularli
upadacitinib risankizumab /kevin huang cfa
et cfra add share plc total return
model portfolio cfra favor view
pipelin includ promis recent product launch
sensor-aug insulin pump system intelli implant
neurostimul also expect posit updat develop surgic
robot howev cautiou given past delay robot program
commit invest increment billion research
 develop next decad find share trade
ep estim attract valu
target price ep estim
slightli peer higher five-year forward price-to-earnings rang
promis growth opportun pay annual
dividend think boost dividend
juli payment share yield replac abbvi inc
total return model portfolio christoph muir
complaint septemb behalf state california
alleg firm violat insur fraud prevent act
provid kickback healthcar provid throughout california given
develop product concentr humira revenu
recent effort govern agenc increas viabil biosimilar
see increas risk futur earn henc lower
opinion share hold lower target
ep estim multipl near
averag three-year forward pe rang rais ep estim
lower ep look
posit catalyst see strong potenti endometriosi drug orilissa
approv juli gener immunolog asset upadacitnib
et cfra keep buy opinion share inc
keep target in-lin peer
forward ep estim ep vs
ahead view rais ep estim
ep estim sale rose humira sale
imbruvica sale hepat drug mavyret robust
see gain market share also encourag abbv pipelin
progress includ fda approv orilissa elagolix endometriosi
april nda submiss risankizumab treat psoriasi also
believ recent deal regard humira remov
overhang regard biosimilar competit grant
non-exclus licens humira begin juli
pay royalti product launch sept
enter similar deal could begin produc
biosimilar januari /jeffrey loo cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
